Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Key facts

Sponsor

ML Bio Solutions, Inc.

Intervention

BBP-418 (ribitol)(drug)

Enrollment

81 enrolled

Eligibility

12-60 years · All sexes

Timeline

2023 – 2027

Study locations (21)

• Arkansas Children's Hospital, Little Rock, Arkansas, United States
• University of California Irvine, Irvine, California, United States
• University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
• University of Florida, Gainsville, Florida, United States
• University of Iowa, Iowa City, Iowa, United States
• University of Kansas Medical Center, Kansas City, Kansas, United States
• Kennedy Krieger Institute, Baltimore, Maryland, United States
• University of Minnesota, Twin Cities, Minneapolis, Minnesota, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• Oregon Health & Science University (OHSU) - Neurology Clinic - South Waterfront, Portland, Oregon, United States
• The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
• University of Pennsylvania, Philadelphia, Pennsylvania, United States
• Children's Hospital of the Kings Daughters, Norfolk, Virginia, United States
• Royal Brisbane and Women's Hospital,, Brisbane, Queensland, Australia
• Rigshospitalet, Neuromuscular Clinic and Research Unit, Copenhagen, Denmark
• +6 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for FKRP-related limb-girdle muscular dystrophy R9

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT04800874
  Study of BBP-418 in Patients With LGMD2I
  ML Bio Solutions, Inc.

See all trials for FKRP-related limb-girdle muscular dystrophy R9 →